INSIGHTEC, INC.
DALLAS, TX

INSIGHTEC WINS GOLD FOR: First MRI-guided focused ultrasound platform FDA-approved to treat essential tremor. For more information: The INSIGHTEC INSIGHTEC was included in the World Medical Innovation Forum’s “Disruptive Dozen” list Specifically, INSIGHTEC was recognized for its Neurology solution, combining transcranial MRI-guided focused ultrasound and focused ultrasound with microbubbles that allow physicians to target tissues deep within the body through the use of sound waves, as opposed to incisions and radiation. Focused ultrasound has the ability to revolutionize the treatment of conditions such as brain cancer and Alzheimer’s through its potential for greater precision and quicker patient recovery. The World Economic Forum has selected INSIGHTEC as one of its Technology Pioneers for 2008 The World Economic Forum appointed a panel of leading technology experts to select finalists from a pool of 273 nominees. INSIGHTEC’s vision is to develop next generation, non-invasive, outpatient operating room that minimizes trauma, morbidity and recovery time. The company’s Exablate® 2000 is the world’s first and only non-invasive surgery system to combine focused ultrasound and magnetic resonance imaging. Red Herring magazine has named INSIGHTEC to its Red Herring 100 Europe 2007 list of the top privately-held technology companies in Europe, the Middle East and Africa (EMEA). Red Herring lists of top private companies are an important part of the company’s tradition of identifying new and innovative technology companies and entrepreneurs. Companies like Google, eBay and Skype were spotted in their early days by Red Herring editors, and touted as leaders that would change the way we live and work. Red Herring editorial staff rigorously evaluates entrepreneurial companies in a careful analysis of financial data and subjective criteria, including quality of management, execution of strategy, and dedication to research and development. INSIGHTEC was the winner of Frost and Sullivan’s 2005 Technical Innovation Award INSIGHTEC was the winner of Frost and Sullivan’s 2005 Technical Innovation Award in the field of non-invasive medical devices for outstanding industry achievement. Frost & Sullivan, the international growth consulting firm, recognized INSIGHTEC as its Exablate® 2000 was the first U.S. Food and Drug Administration (FDA) approved Magnetic Resonance-guided Focused Ultrasound (Exablate MRgFUS) technology for the non-invasive treatment of uterine fibroids. INSIGHTEC’s Exablate Neuro was awarded the Wall St. Journal's Technology Innovation Award - Bronze Winner! The award recognizes technological breakthroughs by individuals, companies and organizations around the world in a wide range of areas, including medicine, software, hardware, the Internet, wireless and broadcasting. “Through these awards, The Wall Street Journal seeks to recognize innovation—and each of these winners embodies the creative thinking that enabled them to rise the top of their respective industries,” said Karen Elliott House, publisher, The Wall Street Journal, and senior vice president, Dow Jones & Company. “We also believe that in today’s business environment, it has never been more important to discover and nurture new ideas". INSIGHTEC is your partner for MR-guided focused ultrasound. We understand that having our state-of-the-art Exablate platform is only the starting point. As your partner for success, we offer clinical and commercial support, maintenance services, marketing support as well as access to our cumulative knowledge and experience from working with leading experts around the world. INSIGHTEC builds long-term relationships with every clinical site to ensure success by providing training programs, clinical support, service and commercial development support. INSIGHTEC AND YOU We have a dedicated team of specialists, per application whose main objective is to provide you with the clinical support and training in order to achieve clinical proficiency. As part of our commitment to you, we will assign a clinical specialist who will personally supervise and guide you through your treatments, using the INSIGHTEC Exablate MRgFUS platform. The team will accompany you until your site is fully operational and certified, and will provide further clinical assistance on an ongoing basis, or as needed. BUSINESS SUPPORT We understand that clinical success is a must, but at the same time, it has to go hand-in-hand with commercial success. Our commercial development team will work closely with you to provide insights and guidance around all of the following commercial aspects: - Getting the organization aligned and everyone on board with the INSIGHTEC platform implementation - Dealing with reimbursement issues and deciding on the best business models to go with the treatment We understand the importance of a smooth and safe operation of our system. Our service engineers will be on-site, periodically, to maintain and service the INSIGHTEC system. They are fully trained and are there to make sure the system performs exactly as it should. Feel free to contact our customer support team with any issues you may have. Whether you are looking for technical support, replenishing your consumables inventory, consultation concerning clinical issues, logistics, shipping arrangements, etc. - our team is here to help you, our customer. Jun (Jim) Tao is INSIGHTEC’s Chief Commercial Officer. Prior to joining INSIGHTEC, Jun was VP of Strategy and Business Development at Constellium where he was responsible for mergers and acquisitions and additional business development activities. Prior to Constellium, he was a Managing Director of CITIC Capital Holdings, a leading private equity firm where he had various managerial roles for the firm’s portfolio of companies. Before CITIC Capital, Jim founded the China operations for American Securities LLC, a NYC-based private equity. Prior to that, Jim served in various management and operations roles with the General Electric Company.